Article Sidebar
Published:
Oct 2, 2015Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Plasma Pharmacokinetic and Heart Distribution Studies of Z-GP-EPI, a Hypocardiotoxic Prodrug of Epirubicin
Abstract
Purpose: To explore the plasma pharmacokinetics and heart distribution of Z-GP-EPI, a low cardiotoxic prodrug of epirubicin (EPI).
Methods: The drugs were administered to 20 rats (11. 22, 44 μmol/kg) by intravenous injection and 70 mice (30 μmol/kg) by tail intravenous injection. The profiles of Z-GP-EPI and EPI in rat plasma or mice heart were determined by high performance liquid chromatography (HPLC) method, which employed the Octadecylsilyl (ODS) column with a mobile phase of acetonitrile : 0.1 % trifluoroacetic-water (42:58, v/v) at a flow rate of 1.0 mL/min and an ultraviolet (UV) detector at a wavelength of 495 nm. Pharmacokinetics parameters were calculated using a pharmacokinetic software.
Results: Relative standard deviation (RSD) of intra- and inter-day precision values was < 15 % in each case while method accuracy with recovery was between 85 and 110 % for plasma and heart samples. After administration of 22 umol/kg Z-GP-EPI or EPI, terminal elimination half-life (t1/2) of Z-GP-EPI (1.41 h) was smaller than that of EPI (12.24 h). Furthermore, the concentration of Z-GP-EPI in heart rapidly decreased from 17.3 μg/g (0.05 h) to undetectable levels (2 h) while EPI changed from 14.3 μg/g (0.05 h) to 9.5 μg/g (2 h).
Conclusion: The HPLC method established in this study is a feasible approach to detecting Z-GP-EPI and EPI in plasma and heart tissue. In addition, Z-GP-EPI is eliminated more rapidly from plasma and heart tissue than EPI, which probably contributes to the low cardiotoxicity of Z-GP-EPI.
Keywords: N-Benzyloxycarbony-prolinyl-glycinyl epirubicin (Z-GP-EPI), Epirubicin, Prodrug, Hypocardiotoxic, Pharmacokinetics, Heart distribution
